VCN BIOSCIENCES SL is the leader of different collaborative projects:

VIRAHN project: Combining VCN-01 with an immunocheckpoint inhibitor (anti-PD-L1 antibody) for the treatment of patients with recurrent/metastatic squamous cell carcinoma of the Head and Neck Phase 1 who has experienced previous resistance to PD1/PD-L1 checkpoint inhibitors. This project is based in a Phase 1 clinical trial, in collaboration with INSTITUT CATALÀ D'ONCOLOGIA and has Astra Zeneca as partner of choice.

Project Cure4RB project: Development of VCN-01 for pediatric retinoblastoma and Phase 1 clinical trial (RTC-2015-4319-1), in which the following partners have been implied: FUNDACIÓ HOSPITAL SANT JOAN DE DÉU, REIG JOFRÉ GROUP, & INSTITUT CATALÀ D'ONCOLOGIA. This project has received funding from Spanish MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD and the European Union (FEDER) by means of RETOS program in its 2015 call.

Project ADELVAC project: ADENOVIRUS with epitope deletions for vaccinacion (IPT-2012-0551-010000), in which the following partners have been implied: REIG JOFRÉ GROUP, INSTITUT CATALÀ D'ONCOLOGIA & INSTITUTO DE SALUD CARLOS III. This project has received funding from Spanish MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD and the European Union (FEDER) by means of INNPACTO program in its 2012 call la Frase.